The University of California, Davis, collaborative model for biotechnology education and training

UC Davis and its partners are addressing the need for innovation and entrepreneurship in graduate education and training. This paper will showcase the Designated Emphasis in Biotechnology graduate education program, cross-disciplinary partnerships and technology brokering. These interactions can bring diverse groups of individuals together to translate ideas into real world applications. The creation of intellectual and human capital at universities must be linked to financial capital and social capital. This can be accomplished by creating dense social networks. PhD programs in science and engineering must be transformed in order to stay relevant in the 21^st century. UC Davis has been addressing these issues for close to 20 years and is now seeing significant outcomes.

Full details at the Journal of Commercial Biotechnology

0 Likes

/0 Tweets/in Biotechnology Industry News

September 30, 2012

30 Sep 2012

Global Health Diplomacy and Management Mechanisms of US-China Public Health Collaborations in China: Lessons for Emerging Markets

China is the largest emerging market in the world. It is also on the front lines of health diplomacy, where the tools of diplomatic statecraft are being employed by public health professions of both the US and China to help improve the practice of public health. This article examines the US Department of Health and Human Services’ (HHS) and the US Centers for Control and Prevention (US CDC) in China, describes critical features of the Chinese health system, presents two examples of US-China collaborations, and describes common management mechanisms and strategies supporting both. This examination will help inform other global health collaborations between the US and China as well as lessons for supporting global health collaborations in other middle income countries.

Full details at the Journal of Commercial Biotechnology

0 Likes

/0 Tweets/in Biotechnology Industry News

September 30, 2012

30 Sep 2012

Blood Supply and Safety in the Developing World: Considerations for Emerging Markets

Assuring a safe and adequate blood supply in developing nations such as emerging markets is a daunting challenge that directly affects fundamental health metrics of a country. Numerous mortalities can be reduced when an effective national blood transfusion system is in place including leading causes of death such as maternal hemorrhage, sickle cell anemia, and malaria. There exists a circular relationship between blood supply and safety: efforts to ensure donor and recipient safety reduce the population of eligible voluntary blood donors, which in turn restricts blood supply. In this article we describe the main issues for blood supply in developing nations and emerging markets, identify the major causes and impact of transfusion transmitted infections, present a safety model that describes the relationship between defensive barriers in depth to assure safe blood, its effectiveness, and the impact it has on safe blood supply. We use twenty two nations in sub-Sahara Africa to present the safety model. Finally, we discuss strategies for blood safety and supply in developing nations.

Full details at the Journal of Commercial Biotechnology

0 Likes

/0 Tweets/in Biotechnology Industry News

September 30, 2012

30 Sep 2012

Lessons on Emerging Markets and Global Health

Full details at the Journal of Commercial Biotechnology

0 Likes

/0 Tweets/in Biotechnology Industry News

September 30, 2012

30 Sep 2012

Globalization, Evolution and Emergence of Direct-to-Consumer Advertising: Are Emerging Markets the Next Pharmaceutical Marketing Frontier?

Pharmaceutical marketing has rapidly evolved over the past century and has now entered the digital revolution. This is exemplified by the rise of direct-to-consumer-advertising (“DTCA”), which has traditionally been only allowed in the United States and New Zealand in developed countries, but is now expanding in reach to other jurisdictions. Enabling the “globalization” of pharmaceutical DTCA is Internet-related technologies that are not limited to geographical borders and are highly unregulated. This DTCA digital “spillover” into markets that prohibit it can have adverse impact on health outcomes and health-related spending. Emerging markets may represent the next logically step for digital DTCA proliferation, given their untapped market potential and explosive growth. Further research and global health policy reform is necessary to address this “emerging” global health issue.

Full details at the Journal of Commercial Biotechnology

0 Likes

/0 Tweets/in Biotechnology Industry News